CA Patent

CA3102105A1 — Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Assigned to PTC Therapeutics MP Inc · Expires 2019-12-05 · 6y expired

What this patent protects

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma exposure of BH4.

USPTO Abstract

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma exposure of BH4.

Drugs covered by this patent

Patent Metadata

Patent number
CA3102105A1
Jurisdiction
CA
Classification
—
Expires
2019-12-05
Drug substance claim
No
Drug product claim
No
Assignee
PTC Therapeutics MP Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.